Publicwire
BioTech Stock IMUN Announces Update on Its Promising Treatment in Immune-Related Diseases and Cancer Therapies
View in Browser

July 31, 2018 - Tuesday

PublicWire Press Release

Immune Therapeutics Inc Announces Publication of Peer Reviewed Scientific Paper Describing Low-Dose Naltrexone (LDN): A Promising Treatment in Immune-Related Diseases and Cancer Therapies Does IMUN Have Serious Upside Potential in the BioTech Sector?

 
 
 
 

IMMUNE THERAPEUTICS, INC.
Ticker: IMUN
https://www.Immunetherapeutics.com

Immune Therapeutics Inc Announces Publication of Peer Reviewed Scientific Paper Describing Low-Dose Naltrexone (LDN): A Promising Treatment in Immune-Related Diseases and Cancer Therapies

Immune Therapeutics, Inc. (OTCQB:IMUN) (“Immune” “IMUN” or the “Company”), a clinical late stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDS, announced the publication of a peer reviewed scientific paper describing LDN as a promising treatment in immune related disease and cancer therapies as identified in the lab by Dr. Fengping Shan, IMUN’s Chief Scientific Officer.

The scientific paper by Fengping and Griffin et al. entitled, Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapies was recently published in the online edition of the International Immunopharmacology.

In this paper, the authors describe and analyze naltrexone, a non-selective antagonist of opioid receptors, is mainly used as rehabilitation therapy for discharged opiate addicts to eliminate addiction in order to maintain a normal life and prevent or reduce relapse. In recent years, there have been some novel and significant findings on the off-label usage of naltrexone. Within a specific dosage window, LDN can act as an immunomodulator in multiple autoimmune diseases and malignant tumors as well as alleviate the symptoms of some mental disorders.

The results of increasing studies indicate that LDN exerts its immunoregulatory activity by binding to opioid receptors in or on immune cells and tumor cells. These new discoveries indicate that LDN may become a promising immunomodulatory agent in the therapy for cancer and many immune-related diseases. In this article, we review the pharmacological functions and mechanisms of LDN as well as its clinical therapeutic potential as revealed by our team and other researchers.

Until now, no review specific focused on the immunoregulatory functions of LDN has been reported. In this article, we provide a comprehensive summary of the immune-related pharmacological functions and potential mechanisms of LDN.

To our knowledge, LDN could modulate the immune system function of the body to resist an abnormal immune response, and it has been widely accepted by patients with MS, IBD such as CD and many types of malignant tumors. Successful reports of patients with fibromyalgia, ALS and type 1 diabetes treated with LDN are increasing. Future studies and clinical work are warranted to confirm the role of LDN in the treatment of immune-related diseases.

LDN may be considered as a novel immunomodulator and tumor biotherapy agent, which is routinely recommended for people with autoimmune diseases and cancer. At the same time, researchers also found that LDN could control appetite and the intake of high-sugar and high-fat foods and that the effect and mechanism of LDN on body weight control were of great value. Moreover, it is believed that LDN will have more novel dosage forms, such as passive transdermal delivery, liquid nasal spray and sustained-release preparations , in the near future.

Although there are many advantages of LDN therapy, such as low cost, low adverse reaction, high safety, easy availability and better compliance, some issues are still worth noting. Since LDN is thought to play a role in the regulation of inflammatory mediators and the upregulation of endogenous opioid receptors, physicians should be alert to patients who have prior chronic use of LDN in pain management when using exogenous opioids in order to prevent hypersensitivity to exogenous opioids.


IMMUNE THERAPEUTICS, INC.
Ticker: IMUN


Notice and Disclaimer:
The content of this message is published by Publicwire LLC. It contains stock alerts, ideas and/or featured stock reports which are intended to be educational in nature, NOT investment recommendations. Please do your own research before investing. It is crucial that you at least look at current SEC filings and read the latest press releases. Information contained in this report was extracted from current documents filed with the SEC, company web sites and other publicly available sources deemed reliable. This document contains forward-looking statements, particularly as related to the business plans of a Company, within themeaning of Section 27A of the Securities Act of 1933 and Sections 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created by these sections. Actual results may differ materially from a Company's expectations and estimates. Feature stock alerts, trading ideas and Reports may, from time-to-time, be advertisements. The purpose of advertising, like any advertising, is to provide coverage and awareness for companies. The information provided in this advertisement is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country. This report is an advertisement. Publicwire has been compensated in cash for services rendered (including this email) by a third party and/or the company. Publicwire does not accept any form of stock (free trading stock, restricted stock, stock options, stock warrants) as payment for its digital investor relations services. The information set forth herein was obtained from sources believed to be reliable, but Publicwire, does not guarantee its accuracy or completeness. For further information on this company, please email Publicwire at ddonlin@publicwire.com.

All Rights Reserved – Publicwire LLC is not a Registered Broker/Dealer or Financial Advisor, nor do we hold ourselves out to be. All materials presented on our web site and individual reports released to the public through this web site, e-mail or any other means of transmission are not to be regarded as investment advice and are only for informative purposes. Before making a purchase or sale of any securities featured on our web site or mentioned in our reports, we strongly encourage and recommend consultation with a registered securities representative. This is not to be construed as a solicitation or recommendation to buy or sell securities. As with any stock, companies we select as picks or stocks we profile involve a high degree of investment risk and volatility. Particularly Nano-Caps, Micro-Caps, Small-Caps, OTCBB and PINKSHEET stocks; but also risky are stock that trade within the broader markets, including the NYSE, AMEX, NASDAQ and other stock U.S and foreign exchanges. All investors are cautioned that they may lose all or a portion of their investment if they decide to make a purchase in any of our profiled companies. Past performance of our profiled stocks is not indicative of future results. The accuracy or completeness of the information on our web site or within our reports is only as reliable as the sources they were obtained from. The profile and opinions expressed herein are expressed as of the date the profile is posted on site and are subject to change without notice. No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. Publicwire may or may not hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our web site or within our reports. In order to be in full compliance with the Securities Act of 1933, Section 17(b), Publicwire will disclose in it's disclaimer's) what, if any compensation was received for our efforts in researching, presenting and disseminating information to our subscriber database, recording and publishing of Reports in the paragraph above. Information presented on our web site and within our reports contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates and projections atthe time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as "expects"", "will," "anticipates," "estimates, "believes," or that by statements indicating certain actions "may," "could," or "might" occur.

Forward Looking Statements
Publicwire content contained here include forward-looking statements that reflect current expectations about future results, performance, prospects and opportunities. Publicwire has tried to identify these forward-looking statements by using words and phrases such as "may," "will," "expects," "anticipates," "believes," "intends," "estimates," "plan," "should," "typical," "preliminary," "we are confident" or similar expressions. These forward-looking statements are based on information currently available and are subject to a number of risks, uncertainties and other factors that could cause actual results, performance, prospects or opportunities to differ materially from those expressed in, or implied by, these forward-looking statements. These risks, uncertainties and other factors include, without limitation, a Company's growth expectation and ongoing funding requirements, and specifically, a Company's growth prospects with scalable customers, and those outlined above. Other risks may include a Company's limited operating history, a Company's history of operating losses, consumers' acceptance, a Company's use of licensed technologies, risk of increased competition, the potential need for additional financing, the terms and conditions of any financing that is consummated, the limited trading market for the Company's securities, the possible volatility of the Company's stock price, the concentration of ownership, and the potential fluctuation in a Company's operating results.

THE READER SHOULD VERIFY ALL CLAIMS AND PERFORM THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN NANO-CAP, MICRO-CAP AND SMALL-CAP SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.

We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (SEC) at: http://www.sec.gov and/or the Financial Industry Regulatory Authority at: http://www.finra.org. Readers can review all public filings by companies at theSEC's EDGAR page. FINRA has published information on how to invest carefully at its web site. PublicWire's Notice and Disclaimer regarding all distribution of company communications can be found at http://www.publicwire.com/notice-and-disclaimer/.

© 2008-2017 PublicWire.com. All Rights Reserved.
5850 T.G. Lee Blvd | Orlando FL | 32822